Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study | HIV.gov

Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study | HIV.gov

Long-Acting Injectable Form of HIV Prevention Outperforms Daily Pill in NIH Study A pre-exposure prophylaxis regimen containing an investigational long-acting form of the HIV drug cabotegravir injected once every 8 weeks was more effective than daily oral Truvada at preventing HIV acquisition among cisgender men who have sex with men and transgender women who have sex with men in a clinical trial sponsored by the National Institutes of Health. LEARN MORE   Today's Conversation with Dr. Carl Dieffenbach! Tune in today on Facebook or Twitter at 6:00 pm ET to hear about conference highlights from Dr. Carl Dieffenbach.

AIDS 2020: Virtual Video Schedule HIV.gov has a new page dedicated to AIDS 2020: Virtual. Here, you can find links to Live with Leadership conversations and evening recaps with NIH's Dr. Carl Dieffenbach.